Scott Myers
Chairman at DYNAVAX TECHNOLOGIES CORPORATION
Net worth: 218 894 $ as of 2024-03-30
Profile
Scott D.
Myers is currently the Chairman at Dynavax Technologies Corp., Ironshore Therapeutics, Inc., and Convergent Therapeutics, Inc. He previously held positions as President, CEO & Head-Media Contact at Aerocrine AB from 2012 to 2015, President, Chief Executive Officer & Director at Cascadian Therapeutics LLC from 2016 to 2018, President, Chief Executive Officer & Director at AMAG Pharmaceuticals, Inc. in 2020, Chairman & Chief Executive Officer at Rainier Therapeutics, Inc. from 2018 to 2020, President, Chief Executive Officer & Director at Viridian Therapeutics, Inc. in 2023, Chairman at Sensorion SA from 2021 to 2023, Chairman at Harpoon Therapeutics, Inc. from 2018 to 2024, Independent Director at Trillium Therapeutics ULC in 2021, Independent Director at Selecta Biosciences, Inc., Independent Director at Orexo AB from 2012 to 2014, Director at Cartesian Therapeutics, Inc. in 2023, and Senior Vice President-Marketing at DOV Pharmaceutical, Inc. from 2005 to 2007.
He also served as Vice President at UCB SA from 2007 to 2011.
Mr. Myers received an undergraduate degree from Northwestern University and an MBA from The University of Chicago Booth School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-04-16 | 9,500 ( 0.02% ) | 166 345 $ | 2024-03-30 | |
0.05% | 2023-11-12 | 80,845 ( 0.05% ) | 52 549 $ | 2024-03-30 |
| 2023-03-14 | 0 ( -.--% ) | - $ | 2024-03-30 |
Scott Myers active positions
| Companies | Position | Start |
|---|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Chairman | 2021-10-18 |
Ironshore Therapeutics, Inc.
 Ironshore Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ironshore Therapeutics, Inc. operates as a pharmaceutical company. The firm offers HLD-200, HLD-900, the morning routine and the delexis products. It develops commercialization of a proprietary drug delivery system. The company was founded by David Gordon MacLeod Lickrish in 2008 and is headquartered in Toronto, Canada. | Chairman | 2022-04-27 |
Convergent Therapeutics, Inc.
 Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation. | Chairman | - |
Former positions of Scott Myers
| Companies | Position | End |
|---|---|---|
| HARPOON THERAPEUTICS, INC. | Chairman | 2024-03-10 |
| VIRIDIAN THERAPEUTICS, INC. | Chief Executive Officer | 2023-10-28 |
| SENSORION | Chairman | 2023-03-29 |
| TRILLIUM THERAPEUTICS | Director/Board Member | 2021-11-16 |
Training of Scott Myers
| Northwestern University | Undergraduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 6 |
|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| UCB | Health Technology |
| OREXO AB | Health Technology |
| SENSORION | Health Technology |
| HARPOON THERAPEUTICS, INC. | Health Technology |
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
| Private companies | 9 |
|---|---|
DOV Pharmaceutical, Inc.
 DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | Commercial Services |
Aerocrine AB
 Aerocrine AB Electronic Equipment/InstrumentsElectronic Technology Aerocrine AB operates as a specialty pharmaceutical company focused on respiratory disease. The company was founded by Lars E. Gustafsson, Jon Lundberg, Kjell Alving, and Eddie Weitzberg in November 1997 and is headquartered in Uppsala, Sweden. | Electronic Technology |
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
Cascadian Therapeutics LLC
 Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
Ironshore Therapeutics, Inc.
Ironshore Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ironshore Therapeutics, Inc. operates as a pharmaceutical company. The firm offers HLD-200, HLD-900, the morning routine and the delexis products. It develops commercialization of a proprietary drug delivery system. The company was founded by David Gordon MacLeod Lickrish in 2008 and is headquartered in Toronto, Canada. | Health Technology |
Selecta Biosciences, Inc.
 Selecta Biosciences, Inc. BiotechnologyHealth Technology Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA. | Health Technology |
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Health Technology |
Convergent Therapeutics, Inc.
Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Scott Myers
